1-7 of 7
Samuel V. Agresta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Clinical Trials & Observations
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Journal: Blood
Blood (2020) 135 (7): 463–471.
https://doi.org/10.1182/blood.2019002140
Published: 2020
Includes: Supplemental data
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Kha Le, PhD, Russ Wada, PhD, David Dai, PhD, Bin Fan, PhD, Guowen Liu, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Samuel V. Agresta, MD, Hua Yang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1394.
https://doi.org/10.1182/blood-2018-99-109863
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony S. Stein, MD, James M. Foran, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, David Dai, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1812.
https://doi.org/10.1182/blood-2018-99-111264
Published: 2018
Journal Articles

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML)

Daniel A. Pollyea, MD, Martin S. Tallman, MD, Stephane De Botton, Courtney D. DiNardo, MDMSc, Hagop M. Kantarjian, MD, Robert H. Collins, MD, Anthony S. Stein, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Eytan M. Stein, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 638.
https://doi.org/10.1182/blood.V130.Suppl_1.638.638
Published: 2017
Journal Articles

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Eytan M. Stein, MD, Richard M. Stone, MD, Daniel A. Pollyea, MD, Gail J. Roboz, MD, Jessica K. Altman, MD, Courtney D. DiNardo, MDMSc, Stephane de Botton, MD PhD, Nora Tu, PhD, Arlene S. Swern, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Amir T. Fathi, MD MD BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1299.
https://doi.org/10.1182/blood.V130.Suppl_1.1299.1299
Published: 2017